フルテキストURL BreastCancer_24_4_593.pdf BreastCancer_24_4_593_tbl_fig.pdf
著者 Saiga, Miho| Taira, Naruto| Kimata, Yoshihiro| Watanabe, Satoko| Mukai, Yuko| Shimozuma, Kojiro| Mizoo, Taeko| Nogami, Tomohiro| Iwamoto, Takayuki| Motoki, Takayuki| Shien, Tadahiko| Matsuoka, Junji| Doihara, Hiroyoshi|
キーワード BREAST-Q Breast cancer Breast reconstruction Health-related quality of life Satisfaction
発行日 2017-03
出版物タイトル Breast Cancer
24巻
2号
出版者 Japanese Breast Cancer Society
開始ページ 288
終了ページ 298
ISSN 1340-6868
NCID AA1103354X
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
著作権者 https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja
論文のバージョン author
PubMed ID 27179527
DOI 10.1007/s12282-016-0703-6
Web of Sience KeyUT 000395524900012
関連URL isVerionOf https://doi.org/10.1007/s12282-016-0703-6
JaLCDOI 10.18926/AMO/54607
フルテキストURL 70_5_425.pdf
著者 Tamura, Tomoki| Hirata, Taizo| Tabata, Masahiro| Hinotsu, Shiro| Hamada, Akinobu| Motoki, Takayuki| Iwamoto, Takayuki| Mizoo, Taeko| Nogami, Tomohiro| Shien, Tadahiko| Taira, Naruto| Matsuoka, Junji| Doihara, Hiroyoshi|
抄録 Docetaxel is a standard treatment for patients with advanced or recurrent breast cancer. The recommended dose is 60 to 100 mg/m2. Previous study have shown that the tumor response rates of patients who received docetaxel monotherapy at doses of 60, 75, and 100 mg/m2 were 22.1% , 23.3% , and 36.0% , respectively, and there was a significant relationship between the dose and response. In Europe and the United States, docetaxel is approved at a dose of 100 mg/m2, and Japanese guidelines also recommend a dose of 100 mg/m2. However, the approved dose in Japan is up to 75 mg/m2. We have launched a phase I trial evaluating 100 mg/m2 docetaxel in patients with advanced or relapsed breast cancer. The major eligibility criteria are as follows: age ≥20 years, pathologically diagnosed breast cancer, recurrent or advanced breast cancer, a good performance status, and HER2 [human epidermal growth factor receptor 2] negative. The primary endpoint is demonstrated safety of 100 mg/m2 docetaxel. This study will clarify whether 100mg/m2 docetaxel can be administrated safely in Japanese patients with advanced or recurrent breast cancer.
キーワード breast cancer phase I trial docetaxel
Amo Type Clinical Study Protocols
発行日 2016-10
出版物タイトル Acta Medica Okayama
70巻
5号
出版者 Okayama University Medical School
開始ページ 425
終了ページ 427
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 27777441
Web of Sience KeyUT 000388098700018
JaLCDOI 10.18926/AMO/53907
フルテキストURL 69_6_333.pdf
著者 Ito, Maiko| Shien, Tadahiko| Kaji, Mitsumasa| Mizoo, Taeko| Iwamoto, Takayuki| Nogami, Tomohiro| Motoki, Takayuki| Taira, Naruto| Doihara, Hiroyoshi| Miyoshi, Shinichiro|
抄録 We evaluated the usefulness of preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) examinations to predict the pathological features in primary breast cancer. In particular, we evaluated the correlation between the maximum standardized uptake values (SUVmax) obtained by 18F-FDG PET/CT and the Ki67 expression in estrogen receptor (ER)-positive invasive ductal carcinoma (IDC). Primary IDC patients operated between March 2009 and July 2013 at Okayama University Hospital were enrolled. We evaluated the correlations between the SUVmax and age, postoperative pT, histological grade, lymph vascular invasion, status of hormone receptor, human epidermal growth factor receptor 2 (HER2), Ki67 expression and node status. The Ki67 expression was classified as high (>14%) versus low (<14%). We enrolled 138 patients with IDC. Their median SUVmax was 3.85 (range:0-52.57). In a univariate analysis, the SUVmax was significantly related to age, pT, histological grade, lymphovascular invasion, hormone receptor status, HER2 status, node status and Ki67. In the 113 patients with ER-positive IDC, there was a significant correlation between Ki67 and SUVmax (p=0.0030). The preoperative 18F-FDG PET/CT results of IDC patients had significant relationships with pathological status parameters. The determination of the preoperative SUVmax might help classify Luminal A and Luminal B patients among luminal-type breast cancer patients.
キーワード breast cancer invasive ductal carcinoma 18F-fluorodeoxyglucose positron emission tomography/computed tomography maximum standardized uptake values clinicopathological features
Amo Type Original Article
発行日 2015-12
出版物タイトル Acta Medica Okayama
69巻
6号
出版者 Okayama University Medical School
開始ページ 333
終了ページ 338
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2015 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 26690243
Web of Sience KeyUT 000368434500002
著者 Mizoo, Taeko| Taira, Naruto| Nishiyama, Keiko| Nogami, Tomohiro| Iwamoto, Takayuki| Motoki, Takayuki| Shien, Tadahiko| Matsuoka, Junji| Doihara, Hiroyoshi| Ishihara, Setsuko| Kawai, Hiroshi| Kawasaki, Kensuke| Ishibe, Youichi| Ogasawara, Yutaka| Komoike, Yoshifumi| Miyoshi, Shinichiro|
発行日 2013-12-01
出版物タイトル BMC Cancer
13巻
資料タイプ 学術雑誌論文
著者 Itoh, Mitsuya| Iwamoto, Takayuki| Matsuoka, Junji| Nogami, Tomohiro| Motoki, Takayuki| Shien, Tadahiko| Taira, Naruto| Niikura, Naoki| Hayashi, Naoki| Ohtani, Shoichiro| Higaki, Kenji| Fujiwara, Toshiyoshi| Doihara, Hiroyoshi| Symmans, W. Fraser| Pusztai, Lajos|
発行日 2014-01
出版物タイトル Breast Cancer Research and Treatment
143巻
2号
資料タイプ 学術雑誌論文
著者 Hayashi, Tatsuro| Asano, Hiroaki| Toyooka, Shinichi| Tsukuda, Kazunori| Soh, Junichi| Shien, Tadahiko| Taira, Naruto| Maki, Yuho| Tanaka, Norimitsu| Doihara, Hiroyoshi| Nasu, Yasutomo| Huh, Nam-ho| Miyoshi, Shinichiro|
発行日 2012-05
出版物タイトル Journal of Cancer Research and Clinical Oncology
138巻
5号
資料タイプ 学術雑誌論文
タイトル(別表記) Evaluation of a one-step nucleic acid amplification (OSNA) assay for sentinel lymph node metastases in early breast cancer
フルテキストURL 126_25.pdf
著者 溝尾 妙子| 枝園 忠彦| 伊藤 麻衣子| 野上 智弘| 岩本 高行| 元木 崇之| 平 成人| 松岡 順治| 土井原 博義|
抄録  Introduction: The one-step nucleic acid amplification (OSNA) assay is a new method to detect sentinel lymph node (SLN) metastases using cytokeratin 19 (CK19) mRNA in early breast cancer. Here we retrospectively analyzed the advantages and disadvantages of the OSNA assay.  Methods: In a trial period, SLNs were divided into two sections, and we examined one side using the OSNA assay. The other side was examined by pathologists. After this period, we examined whole SLNs using only the OSNA assay. The patients with positive nodes by OSNA assay and/or pathology required axillary dissection.  Results: We examined 27 primary breast cancer patients (36 SLNs) during the trial period. The overall concordance rate between the OSNA assay and pathology results was 91%. In the later period, 157 patients (217 SLNs) were examined. The CK19-positive rate obtained by the OSNA assay was 16.5% (macrometastases OSNA (++) : 7.2%, micrometastases OSNA (+) : 9.2%). The non-SLN positive rate among the CK19-positivecases was 23%. The OSNA assay's false negative was one case in which the expression of CK-19 on the primary tumor and lymph node was not detected.  Conclusions: Our OSNA assay results were comparable to those obtained using a conventional pathological technique. Pathologists and laboratory technicians could save time and effort by using the OSNA assay when seeking the precise diagnosis during surgery.
キーワード OSNA法(OSNA method) センチネルリンパ節(sentinel lymph node) micrometastases CK-19
出版物タイトル 岡山医学会雑誌
発行日 2014-04-01
126巻
1号
開始ページ 25
終了ページ 30
ISSN 0030-1558
関連URL http://www.okayama-u.ac.jp/user/oma/
言語 Japanese
著作権者 Copyright (c) 2014 岡山医学会
論文のバージョン publisher
DOI 10.4044/joma.126.25
JaLCDOI 10.18926/AMO/50409
フルテキストURL 67_3_165.pdf
著者 Shien, Tadahiko| Kinoshita, Takayuki| Seki, Kunihiko| Yoshida, Miwa| Hojo, Takashi| Shimizu, Chikako| Taira, Naruto| Doihara, Hiroyoshi| Akashi-Tanaka, Sadako| Tsuda, Hitoshi| Fujiwara, Yasuhiro|
抄録 While clinical and pathologic responses are important prognostic parameters, biological markers from core needle biopsy (CNB) are needed to predict neoadjuvant chemotherapy (NAC) response, to individualize treatment, and to achieve maximal efficacy. We retrospectively evaluated the cases of 183 patients with primary breast cancer who underwent surgery after NAC (anthracycline and taxane) at the National Cancer Center Hospital (NCCH). We analyzed EGFR, HER2, and p53 expression and common clinicopathological features from the CNB and surgical specimens of these patients. These biological markers were compared between sensitive patients (pathological complete response;pCR) and insensitive patients (clinical no change;cNC and clinical progressinve disease;cPD). In a comparison between the 9 (5%) sensitive patients and 30 (16%) insensitive patients, overexpression of p53 but not overexpression of either HER2 or EGFR was associated with a good response to NAC. p53 (p=0.045) and histological grade 3 (p=0.011) were important and significant predictors of the response to NAC. The correspondence rates for histological type, histological grade 3, ER, PgR, HER2, p53, and EGFR in insensitive patients between CNB and surgical specimens were 70%, 73%, 67%, 70%, 80%, 93%, and 73%. The pathologic response was significantly associated with p53 expression and histological grade 3. The correspondence rate of p53 expression between CNB and surgical specimens was higher than that of other factors. We conclude that the level of p53 expression in the CNB was an effective and reliable predictor of treatment response to NAC.
キーワード breast cancer neoadjuvant chemotherapy predictors
Amo Type Original Article
発行日 2013-06
出版物タイトル Acta Medica Okayama
67巻
3号
出版者 Okayama University Medical School
開始ページ 165
終了ページ 170
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2013 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 23804139
Web of Sience KeyUT Pretreatment Specimen Predicts
JaLCDOI 10.18926/AMO/50407
フルテキストURL 67_3_145.pdf
著者 Ishihara, Setsuko| Taira, Naruto| Kawasaki, Kensuke| Ishibe, Youichi| Mizoo, Taeko| Nishiyama, Keiko| Iwamoto, Takayuki| Nogami, Tomohiro| Motoki, Takayuki| Shien, Tadahiko| Matsuoka, Junji| Doihara, Hiroyoshi| Komoike, Yoshifumi| Sato, Shuhei| Kanazawa, Susumu|
抄録 A high mammographic breast density is considered to be a risk factor for breast cancer. However, only a small number of studies on the association between breast density and lifestyle have been performed. A cross-sectional study was performed using a survey with 29 questions on life history and lifestyle. The breast density on mammography was classified into 4 categories following the BI-RADS criteria. The subjects were 522 women with no medical history of breast cancer. The mean age was 53.3 years old. On multivariate analysis, only BMI was a significant factor determining breast density in premenopausal women (parameter estimate, -0.403;p value, 0.0005), and the density decreased as BMI rose. In postmenopausal women, BMI (parameter estimate, -0.196;p value, 0.0143) and number of deliveries (parameter estimate, -0.388;p value, 0.0186) were significant factors determining breast density;breast density decreased as BMI and number of deliveries increased. Only BMI and number of deliveries were identified as factors significantly influencing breast density. BMI was inversely correlated with breast density before and after menopause, whereas the influence of number of deliveries on breast density was significant only in postmenopausal women in their 50 and 60s.
キーワード breast cancer mammographic breast density life style body mass index
Amo Type Original Article
発行日 2013-06
出版物タイトル Acta Medica Okayama
67巻
3号
出版者 Okayama University Medical School
開始ページ 145
終了ページ 151
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2013 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 23804137
Web of Sience KeyUT 000320747900003
関連URL http://ousar.lib.okayama-u.ac.jp/metadata/50646
著者 Nogami, Tomohiro| Shien, Tadahiko| Tanaka, Takehiro| Nishiyama, Keiko| Mizoo, Taeko| Iwamto, Takayuki| Ikeda, Hirokuni| Taira, Naruto| Doihara, Hiroyoshi| Miyoshi, Shinichiro|
発行日 2012-03-10
出版物タイトル Breast Cancer
資料タイプ 学術雑誌論文
JaLCDOI 10.18926/AMO/48691
フルテキストURL 66_4_357.pdf
著者 Shien, Kazuhiko| Shien, Tadahiko| Soh, Junichi| Ikeda, Hirokuni| Nogami, Tomohiro| Taira, Naruto| Doihara, Hiroyoshi| Miyoshi, Shinichiro|
抄録 Ectopic thymoma is considered to arise from ectopic thymus tissue deposited as a result of the abnormal mislocalization of thymus tissue during the embryonic stage. An 86-year-old man visited our hospital with chief complaints of hoarseness and a mass in his anterior neck. A preoperative needle biopsy of the mass did not yield a definitive diagnosis. A positron emission tomography (PET) study revealed heterogeneous accumulation of <sup>18</sup>F-fluorodeoxyglucose (FDG) in the tumor. The tumor, affecting the left sternocleidomastoid muscle, the recurrent laryngeal nerve, the internal carotid vein, and the brachiocephalic vein, was resected using a combination of a collar incision in the neck and a median incision in the sternum. Immunohistochemically, the tumor was diagnosed as an ectopic thymoma of the neck. To date, only a few cases of ectopic thymoma presenting with FDG accumulation have been reported. Our experience indicates that ectopic thymoma should be kept in mind during the differential diagnosis of neck tumors with FDG accumulation appearing on PET images.
キーワード ectopic thymoma thyroid tumor positron emission tomography (PET)
Amo Type Case Report
発行日 2012-08
出版物タイトル Acta Medica Okayama
66巻
4号
出版者 Okayama University Medical School
開始ページ 357
終了ページ 361
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2012 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 22918209
JaLCDOI 10.18926/AMO/46848
フルテキストURL 65_4_231.pdf
著者 Shien, Tadahiko| Doihara, Hiroyoshi| Nishiyama, Keiko| Masuda, Hiroko| Nogami, Tomohiro| Ikeda, Hirokuni| Taira, Naruto|
抄録 Combined low-dose therapy of oral capecitabine (Xeloda) and cyclophosphamide (XC) has been demonstrated to be useful for long-term control of lesions in patients with metastatic breast cancer (MBC) and is aimed at symptomatic alleviation and prolongation of survival. Here, a retrospective review was conducted of MBC patients administered XC at the Okayama University Hospital (OUH), to evaluate responses to XC, adverse events and time to progression (TTP). Twenty patients with MBC received XC between 2006 and 2009. With the exception of 2 elderly patients who were over the age of 70 at the initial examination, all of the patients had received prior treatment with an anthracycline and/or a taxane. No complete response (CR) cases were observed, but partial response (PR) was achieved in 6 patients (30%) and SD in 9 (45%), of whom 5 (20%) sustained SD status for >12 months. The median TTP was 6 months (range:3-27 mo.). Three patients developed Grade 3 adverse events (diarrhea, nausea and stomatitis), but no other patients developed adverse reactions causing interruption of the therapy. XC was safe even in previously treated and elderly MBC patients;moreover, it yielded remarkable clinical responses.
キーワード metastatic breast cancer metronomic chemotherapy
Amo Type Original Article
発行日 2011-08
出版物タイトル Acta Medica Okayama
65巻
4号
出版者 Okayama University Medical School
開始ページ 231
終了ページ 237
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2011 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 21860529
Web of Sience KeyUT 000294236700003
著者 Taira, Naruto| Shimozuma, Kojiro| Shiroiwa, Takeru| Ohsumi, Shozo| Kuroi, Katsumasa| Saji, Shigehira| Saito, Mitsue| Iha, Shigemichi| Watanabe, Takanori| Katsumata, Noriyuki|
発行日 2011/08
出版物タイトル Breast Cancer Research and Treatment
128巻
3号
資料タイプ 学術雑誌論文
JaLCDOI 10.18926/AMO/31816
フルテキストURL fulltext.pdf
著者 Okita, Atsushi| Saeki, Toshiaki| Aogi, Kenjiro| Osumi, Shozo| Takashima, Shigemitsu| Okita, Riki| Taira, Naruto| Kakishita, Tomokazu| Kurita, Akira|
抄録 <p>Toremifene citrate is expected to prevent drug resistance in cancer patients by inhibiting p-glycoprotein activity. The safety and efficacy of combination therapy with high-dose toremifene citrate and paclitaxel were investigated. Between December 2003 and June 2004, 15 women with a mean age of 53 years old with metastatic breast cancer were enrolled. The administration schedule was 80mg/m2 of paclitaxel given on Days 1, 8, and 15, and 120mg/day of toremifene citrate orally administered starting on Day 18. On Days 32 and 39, paclitaxel was concurrently administered again. Toxicities, response rate, and time to treatment failure were assessed. All patients had been treated with endocrine or chemotherapy. Grade 3 leukopenia occurred in 2 patients on the administration of paclitaxel alone, and grade 3 febrile neutropenia occurred in 1 patient given the combination therapy. There was no grade 3 or greater non-hematological toxicity. There was no complete response and 1 partial response, producing a response rate of 6.7%. Median time to treatment failure was 2.7 months. Combination therapy of paclitaxel and toremifene was safe and well tolerated with minimal toxicity. Further clinical trials targeting patients with functional p-glycoprotein are warranted.</p>
キーワード toremifene paclitaxel p-glycoprotein metastatic breast cancer
Amo Type Original Article
発行日 2009-08
出版物タイトル Acta Medica Okayama
63巻
4号
出版者 Okayama University Medical School
開始ページ 187
終了ページ 194
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 19727203
Web of Sience KeyUT 000269228400004
JaLCDOI 10.18926/AMO/30755
フルテキストURL fulltext.pdf
著者 Taira, Naruto| Doihara, Hiroyoshi| Oota, Tetsuya| Hara, Fumikata| Shien, Tadahiko| Takahashi, Hirotoshi| Yoshitomi, Seiji| Ishibe, Youichi| Shimizu, Nobuyoshi|
抄録 <p>Human esophageal cancers have been shown to express high levels of epidermal growth factor receptor (EGFR) and a relationship between high EGFR expression and local advance, the number of lymph node metastases, life expectancy, and sensitivity to chemo-radiotherapy has been demonstrated. We examined the use of gefitinib, an orally active EGFR-selective tyrosine kinase inhibitor, as a new strategy for treatment of esophageal carcinoma. The effects of gefitinib were evaluated in monotherapy and in combination with radiotherapy in human esophageal carcinoma cell lines. Gefitinib produced a dose-dependent inhibition of cellular proliferation in all of the 8 esophageal carcinoma cell lines examined, with IC50 values ranging from 5.7 microM to 36.9 microM. In combination, gefitinib and radiotherapy showed a synergistic effect in 2 human esophageal carcinoma cell lines and an additive effect in 5 cell lines. Western blotting demonstrated that gefitinib blocked activation of the EGFR-extracellular signal-regulated kinase (Erk) pathway and the EGFR-phosphoinositide-3 kinase (PI3K)-Akt pathway after irradiation. These results suggest that further evaluation of EGFR blockade as a treatment for esophageal cancer should be performed, and that radiotherapy combined with EGFR blockade may enhance the response of esophageal carcinoma to therapy.</p>
キーワード gefitinib esophageal cancer radiosensitivity epidermal growth factor receptor
Amo Type Article
発行日 2006-02
出版物タイトル Acta Medica Okayama
60巻
1号
出版者 Okayama University Medical School
開始ページ 25
終了ページ 34
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 16508686
Web of Sience KeyUT 000235538900003
著者 土井原 博義| 平 成人|
発行日 2008-01-04
出版物タイトル 岡山医学会雑誌
119巻
3号
資料タイプ 学術雑誌論文